



- Seven MPP licensees are working on ATV/r formulation, of which:
 - **Cipla, Emcure** and **Mylan** have received USFDA approvals; of which **Mylan** and **Emcure** have already commercialised the product
 - **Cipla** and **Mylan** have received WHO-PQ approvals
 - Additionally four companies are planning to file the product in 2019
- Currently approved in 32 countries and filed in another 16 countries
 - Total filing coverage: 94.2% of PLHIV in LMICs